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■ LETTER TO THE EDITOR ■
Endometrial cancer is a common disease of peri-
menopausal and postmenopausal women. The com-
mon histologic type is endometrioid adenocarcinoma.
Adenosarcoma is among the rarest type of endometrial
cancer, and is by definition a malignant tumor composed
of morphologically malignant stroma and benign glan-
dular epithelium. Here, we report two uncommon cases
of endometrial adenosarcoma. The clinical course, treat-
ment and histopathologic features of the tumors are
reviewed and discussed.
In the first case, a 46-year-old married Taiwanese
woman, gravida 0, para 0, with a history of diabetes
mellitus presented with vaginal bleeding for 1 month.
A thickened endometrium, measuring up to 3.14 cm,
was noted on sonography. Diagnostic dilatation and
curettage was done with subsequent radical surgery
composed of total hysterectomy, bilateral salpingo-
oophorectomy, omentectomy, and bilateral para-aortic
and pelvic lymph node dissections. Histopathologic
examination showed a tumor exhibiting exophytic growth
from the endometrium, consisting of polypoid cleft-
like glands surrounded by a cuff of cellular parenchyma.
The epithelial component was cytologically bland and
the mesenchymal component exhibited significant
cytologic atypia and frequent mitoses (> 5 mitoses per
10 high-power fields) (Figures 1 and 2). Immunohisto-
chemical study of the malignant mesenchymal tumor
cells was positive for vimentin, focally positive for
estrogen receptor, and negative for progesterone recep-
tor, desmin, CD10, Her-2/neu, CD117 and epidermal
growth factor receptor (EGFR). An endometrial adeno-
sarcoma was diagnosed. The postoperative course 
of the patient was smooth and she was still being 
followed up regularly at the outpatient department
after 6 months.
In the second case, a 64-year-old woman presented
with postmenopausal bleeding for a period of time. 
A uterine mass, measuring 4×4×2 cm, was noted during
sonographic examination. Diagnostic dilatation and
curettage was performed. Microscopic examination of
the tumor revealed hypercellular stroma with marked
atypia, leaf-like appearance and periglandular stromal
cuffing (Figures 3 and 4). The tumor cells were positive
for estrogen receptor and progesterone receptor but
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Figure 1. Histopathologic examination showing polypoid
cleft-like glands surrounded by a cuff of cellular parenchyma
(low-power field). Small arrow: epithelial component; large
arrow: stromal component.
40 um
Figure 2. Histopathologic examination showing the epithelial
component is cytologically bland, and the mesenchymal
component exhibits significant cytologic atypia and frequent
mitoses (> 5 mitoses per 10 high-power fields). Small arrow:
epithelial component; large arrow: stromal component.
negative for Her-2/neu, CD117 and EGFR. The fluo-
rescence in situ hybridization of Her-2/neu was not
overexpressed (Figure 5). The final pathologic diagnosis
was adenosarcoma of the endometrium. Further treat-
ment was performed at another hospital with a smooth
postoperative course, and the patient was still free of
disease after 4 years’ follow-up, according to medical
records.
Adenosarcoma of the uterine body was first
described by Clement and Scully in 1974 [1]. The tumor
is composed of epithelial and stromal components. The
stromal component is malignant, but the epithelial
component is benign. Adenosarcoma is a rare tumor;
only 10 cases of uterine body sarcoma, other than
endometrial stromal sarcoma, leiomyosarcoma and
malignant mixed müllerian tumor, were registered
between 1996 and 2002, according to the annual
report of the Taiwan Cancer Registry [2].
The important differential diagnosis for adenosar-
coma of the endometrium includes carcinosarcoma
and adenofibroma. Adenofibroma consists of both
bland stroma and epithelium. Carcinomatous and sar-
comatous differentiation must be appreciated in carci-
nosarcoma. These two differential diagnoses cause no
difficulty for experienced pathologists. Although endo-
metrial adenosarcoma and carcinosarcoma are similar
in management, distinction between adenosarcoma
and carcinosarcoma is important owing to different
prognoses and outcomes. They are difficult to differ-
entiate with imaging alone, and a misdiagnosis may 
be made even on histologic examination if the specimen
is too small or is signed out by an inexperienced
pathologist.
The mainstay of treatment for primary endometrial
adenosarcoma is complete surgical resection. The
standard surgical method is radical or total hysterec-
tomy, based on tumor stage, with bilateral salpingo-
oophorectomy, bilateral pelvic lymph node dissection
and omentectomy [3].
There is no standard recommendation for adjuvant
therapy. The use of chemotherapy, radiotherapy 
or concurrent chemoradiotherapy is still under inves-
tigation because of limited experience with this 
malignancy.
A previous report showed overexpression of EGFR
in 33% of adenosarcoma cases [4]. However, both of
our cases were negative for EGFR, CD117 and Her-2/
neu, so the current new therapy target of CD117, 
Her-2/neu and EGFR might have been useless for our
patients.
The recurrence rate of uterine adenosarcoma is
about 25–40% and distant metastases occur in 5% of
patients [5–7]. The recurrences usually consist exclusively
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Figure 3. Histopathologic examination showing leaf-like
appearance and periglandular stromal cuffing (low-power
field). Small arrow: epithelial component; large arrow: stromal
component.
Figure 4. Histopathologic examination showing hypercellular
stroma with marked atypia (high-power field). Small arrow:
epithelial component; large arrow: stromal component.
Figure 5. Fluorescence in situ hybridization stain of Her-2/
neu showing no overexpression. Blue signal: DNA; green 
signal: centrioles; red signal: Her-2/neu.
of the sarcomatous component, but in rare cases,
recurrences can consist of both epithelial and sarco-
matous components [1,5,6]. The histologic features
associated with poor prognosis include extrauterine
spread at diagnosis, myometrial invasion, sarcomatous
overgrowth of the mesenchymal component, lympho-
vascular permeation, and presence of a rhabdomyosar-
coma element [1,7]. Long-term follow-up is necessary
for the common delayed recurrence that occurs 3–5
years postoperatively [1]. Death from adenosarcoma
is reported in about one-quarter of patients. The inter-
val between initial diagnosis and death is often more
than 5 years, if no obvious stromal overgrowth is
noted [8].
In conclusion, primary endometrial adenosarcoma
is rare. It should be carefully differentiated from ade-
nofibroma and carcinosarcoma because of different
clinical outcomes. Once the diagnosis of endometrial
adenosarcoma is made, thorough preoperative imag-
ing studies and postoperative pathologic examina-
tions are important, since adenosarcoma with stromal
overgrowth has a poorer prognosis. More clinical and
pathologic experience is required with this uncommon
entity.
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